Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Lorenza Rimassa, MD
Humanitas Cancer Centre, IRCCS Humanitas Research Hospital
Principal Investigator - Stephen Chan, MD
Department of Clinical Oncology, Chinese University of Hong Kong
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
40 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
Bobigny, France
- Research Site
Clichy, France
- Research Site
Créteil, France
- Research Site
Marseille, France
- Research Site
Rennes, France
- Research Site
Berlin, Germany
- Research Site
Cologne, Germany
- Research Site
Frankfurt, Germany
- Research Site
Lübeck, Germany
- Research Site
Hong Kong, Hong Kong
- Research Site
Shatin, Hong Kong
- Research Site
Milan, Italy
- Research Site
Naples, Italy
- Research Site
Padova, Italy
- Research Site
Pisa, Italy
- Research Site
Rozzano, Italy
- Research Site
Turin, Italy
- Research Site
Kanazawa, Japan
- Research Site
Kashiwa, Japan
- Research Site
Matsuyama, Japan
- Research Site
Musashino-shi, Japan
- Research Site
Osakasayama-shi, Japan
- Research Site
Yokohama, Japan
- Research Site
Singapore, Singapore
- Research Site
Singapore, Singapore
- Research Site
Singapore, Singapore
- Research Site
Gyeonggi-do, South Korea
- Research Site
Seongnam-si, South Korea
- Research Site
Seoul, South Korea
- Research Site
Seoul, South Korea
- Research Site
Seoul, South Korea
- Research Site
Barcelona, Spain
- Research Site
Córdoba, Spain
- Research Site
Madrid, Spain
- Research Site
Madrid, Spain
- Research Site
Pamplona, Spain
- Research Site
La Jolla, California, United States
- Research Site
Shreveport, Louisiana, United States
- Research Site
Detroit, Michigan, United States
- Research Site
Hanoi, Vietnam
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 27 Jun 2023
- Primary completion
- 30 Mar 2026
- Completion
- 30 Sept 2026
- Last update posted
- 30 Apr 2026
- Registered enrollment
- 111
- Registry id
- NCT05883644
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.